Artivion Proxy Filing Discloses Board Slate, Pay Artivion filed a DEF 14A on Apr 6, 2026 (Investing.com); review board slate and pay disclosures now ahead of the May-June proxy season.

Artivion Proxy Filing Discloses Board Slate, Pay: Artivion filed a DEF 14A on Apr 6, 2026 (Investing.com); review board slate and pay disclosures now ahead of the May-June proxy season. 👈 Read full analysis #Artivion #ProxyFiling #BoardSlate #ExecutivePay #Investing

Artivion Unveils Promising Clinical Data on Aortic Disease Treatments at STS Annual Meeting Artivion, Inc. recently showcased groundbreaking clinical data from the NEXUS TRIOMPHE and AMDS PERSEVERE trials at the Society of Thoracic Surgeons Annual Meeting, highlighting significant patient outcomes.

Artivion Unveils Promising Clinical Data on Aortic Disease Treatments at STS Annual Meeting #United_States #New_Orleans #Artivion #NEXUS_TRIOMPHE #Aortic_Disease

Artivion Reports Impressive Financial Growth in Q3 2025 Amid Strategic Developments Artivion, Inc. showcases remarkable revenue and income growth in the third quarter of 2025, highlighting strategic advancements and positive clinical outcomes.

Artivion Reports Impressive Financial Growth in Q3 2025 Amid Strategic Developments #United_States #Atlanta #Artivion #FinancialResults #Arcevo

Artivion's ARTIZEN Trial Marks Milestone with First Patient Treated Using Arcevo LSA Artivion, Inc. has successfully treated the first patient in the ARTIZEN trial, designed to assess the Arcevo LSA Hybrid Stent Graft System for aortic arch pathologies.

Artivion's ARTIZEN Trial Marks Milestone with First Patient Treated Using Arcevo LSA #United_States #Atlanta #Artivion #Arcevo_LSA #ARTIZEN_Trial

Artivion Set to Showcase Innovations at Stifel 2025 Healthcare Conference Artivion, Inc. will present at the Stifel 2025 Healthcare Conference on November 12. Join their webcast for insights into cardiac care innovations.

Artivion Set to Showcase Innovations at Stifel 2025 Healthcare Conference #United_States #healthcare #Atlanta #Artivion #Stifel2025

Artivion to Showcase Innovations at Morgan Stanley Healthcare Conference Artivion is set to participate in the Morgan Stanley 23rd Annual Global Healthcare Conference, addressing advancements in aortic disease treatment.

Artivion to Showcase Innovations at Morgan Stanley Healthcare Conference #USA #healthcare #Atlanta #Artivion #Aortic_Disease

Artivion's Strong Second Quarter 2025 Financial Performance Highlights Significant Growth Artivion, Inc. reported impressive financial results for Q2 2025, showcasing remarkable growth in revenue and net income, alongside major developments in product approval.

Artivion's Strong Second Quarter 2025 Financial Performance Highlights Significant Growth #United_States #Atlanta #financial_results #Artivion #Aortic_Disease

Artivion Set to Engage Investors at Major Upcoming Conferences Artivion, Inc. is gearing up to present at significant investor conferences, focusing on innovations in cardiac surgery related to aortic disease. Don't miss out!

Artivion Set to Engage Investors at Major Upcoming Conferences #USA #Investor_Conferences #Artivion #Atlanta,_Georgia #Aortic_Disease

Artivion Inc. Set to Showcase Innovations at Two Investor Conferences Artivion, Inc. announces its participation in two significant investor conferences focused on cardiac and vascular surgery, featuring key presentations.

Artivion Inc. Set to Showcase Innovations at Two Investor Conferences #USA #Atlanta #Artivion #Cardiac_Surgery #AORT

Artivion Strengthens Financial Position With Successful Exchange of Convertible Notes for Common Stock Artivion, Inc. has successfully closed transactions exchanging $99.5 million in convertible notes for shares, enhancing its financial strength and reducing debt.

Artivion Strengthens Financial Position With Successful Exchange of Convertible Notes for Common Stock #United_States #Atlanta #Convertible_Notes #Artivion #Aortic_Disease

Artivion Pursues Strategic Exchange of $95 Million Convertible Notes for Shares Artivion, Inc. announces a plan to exchange $95 million in convertible notes for common stock, enhancing shareholder value and reducing debt risk.

Artivion Pursues Strategic Exchange of $95 Million Convertible Notes for Shares #USA #Atlanta #Convertible_Notes #Artivion #Aortic_Disease

Artivion Announces Strong Financial Performance for Q1 2025: Revenue Growth and Strategic Advancements In Q1 2025, Artivion reported a revenue increase to $99 million, showing growth against prior year. Notable accomplishments highlight their resilience post-cybersecurity incident.

Artivion Announces Strong Financial Performance for Q1 2025: Revenue Growth and Strategic Advancements #United_States #Atlanta #financial_results #Artivion #Aortic_Disease

Artivion Showcases Promising Clinical Outcomes at AATS Annual Meeting Artivion, Inc. recently presented groundbreaking clinical data at the AATS annual meeting, revealing significant advances in treating chronic aortic dissection.

Artivion Showcases Promising Clinical Outcomes at AATS Annual Meeting #USA #Seattle #Artivion #AATS #NEXUS_TRIOMPHE

Artivion Celebrates Strong Financial Results for 2024 with Significant Revenue Growth Artivion, a leader in cardiac and vascular surgery, reports impressive financial growth for the fourth quarter and full year 2024, highlighting advances in technology.

Artivion Celebrates Strong Financial Results for 2024 with Significant Revenue Growth #United_States #Atlanta #Artivion #AMDS #AORT

Artivion Unveils Promising Data from AMDS Trial at Major Surgery Meeting Artivion presents groundbreaking results from the AMDS PERSEVERE trial, showcasing significant improvements in outcomes for patients with acute aortic dissections.

Artivion Unveils Promising Data from AMDS Trial at Major Surgery Meeting #United_States #Los_Angeles #Artivion #AMDS #ClinicalTrial

Ransomware attack hits leading heart surgery device maker ​Artivion, a leading manufacturer of heart surgery medical devices, has disclosed a November 21 ransomware attack that disrupted its operations and forced it to take some systems offline.

#Artivion, a leading manufacturer of heart surgery medical devices, has disclosed a November 21 ransomware attack that disrupted its operations and forced it to take some systems offline. #Ransomware #CyberAttacks www.bleepingcomputer.com/news/securit...

Revolutionizing Aortic Care: Artivion's AMDS Hybrid Prosthesis Receives FDA Exemption Artivion, Inc. has received FDA HDE approval for its innovative AMDS Hybrid Prosthesis, marking a breakthrough in treating aortic dissections.

Revolutionizing Aortic Care: Artivion's AMDS Hybrid Prosthesis Receives FDA Exemption #United_States #Atlanta #FDA_Approval #Artivion #AMDS